Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab ; volume:26 ; number:1 ; day:2 ; month:1 ; year:2024 ; pages:1-10 ; date:12.2024
Arthritis Research & Therapy ; 26, Heft 1 (2.1.2024), 1-10, 12.2024
- Creator
-
Thudium, Christian S.
Frederiksen, Peder
Karsdal, Morten A.
Bay-Jensen, Anne-Christine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-023-03242-0
- URN
-
urn:nbn:de:101:1-2024031409292159851559
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Thudium, Christian S.
- Frederiksen, Peder
- Karsdal, Morten A.
- Bay-Jensen, Anne-Christine
- SpringerLink (Online service)
Other Objects (12)
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Tocilizumab degradation via photo-catalytic ozonation process from aqueous
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy
Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Tocilizumab degradation via photo-catalytic ozonation process from aqueous
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy
Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Tocilizumab degradation via photo-catalytic ozonation process from aqueous
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy
Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series